COMP <GO>
HALO vs UNH // GROSS PROFIT MARGIN
Halozyme Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: HALO 7
— UNH 6
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $128.95 (-1.50%) • MKT CAP: $14.64B
gross-margins
83.60%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 83.60% | 88.31% | -4.71 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.00% | 12.38% | +5.62 | HALO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.6x | 15.3x | +20.33 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.33% | 6.25% | -1.92 | UNH | /fcf-yield <GO> |
| Operating Margin | 33.60% | 5.32% | +28.28 | HALO | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 3.53% | +19.17 | HALO | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 3.33% | +34.27 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 3.09 | +2.02 | HALO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.2 | 55.1 | +14.10 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | HALO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 17.7x | +21.76 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.64B | $359.43B | -$344.80B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | UNH REV | HALO GROSS % | UNH GROSS % | HALO FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $447.57B | 83.6% | 88.7% | $644.6M | $16.07B |
| FY 2024 | $1.02B | $400.28B | 84.3% | 88.3% | $468.4M | $20.70B |
| FY 2023 | $829.3M | $371.62B | — | 89.6% | $351.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
UNH // BETA 0.33